News
-
CMA prevention priority
Wednesday | Sep 7 2016Complementary Medicines Australia (CMA) says the use and further development of complementary medicines "provides an opportunity to counteract spiralling health care costs through more effective disease prevention and preventable chronic disease management".
-
UK pharmacy cuts delayed
Wednesday | Sep 7 2016The proposed 170 million reduction in pharmacy funding in England will be postponed beyond next month, according to UK pharmacy minister David Mowat.
-
Guild Update 6 Sep 16 : Manage stock ahead of 1 October
Tuesday | Sep 6 2016THE 1 October PBS Price Disclosure reductions represent the first Price Disclosure cycle that will incorporate.
-
Dispensary Corner 06 Sep 16
Tuesday | Sep 6 2016HERE'S a novel way to remind pet owners to clean up their animal's droppings: erecting a giant dog poo sculpture buzzing with oversized flies (pictured below) on top of a city bus stop.
-
AHPRA probes medical chaperones
Tuesday | Sep 6 2016The Australian Health Practitioner Regulation Agency has released the terms of reference for an independent review on the use of chaperones to protect patients.
-
New MATES module
Tuesday | Sep 6 2016The Veterans Medicines Advice and Therapeutics Education Services project has released a new training topic covering dementia and changes in behaviour.
-
B Vitamin research
Tuesday | Sep 6 2016a NEW study out of Swinburne University has revealed the role of vitamins and minerals for optimal physiological and neurological functioning.
-
2015 stats available
Tuesday | Sep 6 2016The Health Department has released the Australian Statistics on Medicines (ASM) for 2015, representing estimates of the aggregate community use of prescription medicines in Australia.
-
Mundipharma deal
Tuesday | Sep 6 2016MunDIpharma has announced an expansion of its consumer healthcare business, via a partnership giving it commercial rights to market Munir Sukhtian Group's portfolio of HiGeen treatments in over fifty countries across the Middle East, Africa and Pakistan for the next ten years.
-
Zepatier registered
Tuesday | Sep 6 2016The Therapeutic Goods Administration has registered MSD's Zepatier (elbasvir/grazoprevir) with or without ribavirin, for the treatment of chronic hepatitis C virus genotype 1 and 4 infection in adults.
